Exemestane, Ribociclib, and Everolimus in Women With HR+/HER2− Advanced Breast Cancer After Progression on CDK4/6 Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women With HR+/HER2- Advanced Breast Cancer After Progression on CDK4/6 Inhibitors (TRINITI-1)
Clin. Cancer Res 2021 Jun 18;[EPub Ahead of Print], A Bardia, SA Hurvitz, A DeMichele, AS Clark, A Zelnak, DA Yardley, M Karuturi, T Sanft, S Blau, L Hart, C Ma, HS Rugo, D Purkayastha, S MoulderFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.